Understanding how certain inhibitors can trigger a specific type of cell death.
Characterizing the Mechanism of DPP8/9 Inhibitor-Induced Pyroptosis
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11086842
This study is looking at how certain substances can change the way our immune system's inflammasomes work, which are important for fighting off diseases but can sometimes go into overdrive and cause problems like cancer or autoimmune disorders, with the hope of finding new ways to help people stay healthy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11086842 on ClinicalTrials.gov |
What this research studies
This research investigates how specific inhibitors affect the activation of inflammasomes, which are protein complexes that play a crucial role in immune responses and cell death. By examining the relationship between certain peptides and the activation of these inflammasomes, the study aims to uncover the mechanisms behind their hyperactivation, which can lead to conditions like cancer and autoimmune disorders. The research involves analyzing the molecular interactions and signals that trigger this process, potentially leading to new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune disorders or cancers related to inflammasome activation.
Not a fit: Patients with conditions unrelated to inflammasome activation or those not experiencing autoimmune or cancer-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for autoimmune diseases and cancer by targeting the mechanisms of cell death.
How similar studies have performed: Previous research has shown promising results in understanding inflammasome activation, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BACHOVCHIN, DANIEL — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: BACHOVCHIN, DANIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease